Why it Matters

The Trump administration's decision to impose tariffs of up to 100 percent on imported patented pharmaceuticals has set off a scramble in Washington over who actually benefits from a domestic manufacturing renaissance — and whether small manufacturers can survive it. The Senate Small Business and Entrepreneurship Committee is scheduled to take up that question on May 13, when it convenes a Senate small business hearing on industrialization and the rise of small manufacturers. The stakes extend well beyond pharmaceuticals: the hearing arrives as tariff policy is reshaping supply chains across sectors, and small firms — with less capital, fewer lobbyists, and no economies of scale — are navigating that disruption with fewer tools than their larger competitors.

The Tariff Catalyst

The White House announced in April 2026 that the administration would impose sweeping tariffs on imported patented drugs, framing the move as a national security imperative. "President Trump recognizes that America must manufacture pharmaceutical products in order to be safe, secure, and healthy," the fact sheet read. CNBC reported that companies planning to onshore production would face a 20 percent tariff, scaling to 100 percent over four years for those that do not. The full 100 percent rate takes effect September 29, 2026, according to Ropes & Gray.

The policy is designed to force pharmaceutical production back to American soil. But the Senate Small Business Committee, chaired by Sen. Joni Ernst (R-IA) with Sen. Ed Markey (D-MA) as ranking member, appears poised to examine whether small manufacturers are positioned to absorb that transition — or whether the burden falls disproportionately on them.

The concern is not hypothetical. The American Action Forum has documented that larger firms have economies of scale and greater political influence, noting that trade-related lobbying spiked by close to 30 percent since the implementation of Trump's tariffs, with several large firms already securing exemptions — advantages small manufacturers do not have. The U.S. Chamber of Commerce has cited examples of small manufacturers freezing hiring in response to aluminum tariffs, illustrating the asymmetry in how trade policy lands on firms of different sizes.

Marketplace reported in April 2026 that manufacturing employment one year after Trump's tariffs took effect was lower than the prior year, with economist Matt Notowidigdo observing: "We've got fewer manufacturing jobs than a year ago, which suggests maybe that tariffs weren't having their intended impact."

The Lobbying Landscape

The pharmaceutical manufacturing push has generated a significant lobbying response, with filings directly relevant to the hearing's tagged issue area — pharmaceuticals and drugs — reflecting tens of millions of dollars in activity across the 119th Congress.

Amneal Pharmaceuticals LLC has spent more than $1 million lobbying on "addressing drug shortages and enhancing domestic production of critical medicines." The Association for Accessible Medicines has reported more than $3.4 million in lobbying expenditures on issues including pharmaceutical manufacturing supply chains and generic drug policy.

Smaller, specialized firms are also active. Continuus Pharmaceuticals Inc. has spent $120,000 lobbying specifically on "incentives to reshore pharmaceutical manufacturing." Sentinel API Group Inc. has pushed for federal support for new U.S.-based active pharmaceutical ingredient facilities, explicitly referencing H.R. 1405, the Enhancing Domestic Drug Manufacturing Competitiveness Act, in its filings. Fresenius Kabi USA LLC has reported $770,000 in lobbying on drug shortages and domestic manufacturing.

The American Small Manufacturers Coalition has spent $340,000 lobbying for Manufacturing Extension Partnership funding — a federal program that provides technical assistance to small manufacturers — with filings covering both fiscal year 2026 and fiscal year 2027 appropriations.

Beyond pharmaceuticals, the broader industrialization landscape has attracted significant lobbying activity. Flex Ltd. has spent $300,000 on "policy regarding reshoring manufacturing in the U.S." Phoenix Tailings Inc., which focuses on domestic critical mineral processing, has reported $420,000 in lobbying on onshoring rare earth metal processing.

A Broader Industrial Policy Moment

The hearing fits within a larger congressional and administrative focus on whether the United States can rebuild domestic manufacturing capacity across sectors. The Alliance for American Manufacturing has noted that large factory investments in semiconductors, autos, and steel should generate downstream demand for smaller manufacturers in chemicals, precision equipment, and circuit boards — but that supply chain localization is not automatic and requires smaller firms to have the capital and workforce to scale.

That question — whether small manufacturers can realistically participate in a domestic industrialization push — sits at the center of the May 13th hearing. The Senate Small Business Committee has jurisdiction over the programs, financing mechanisms, and regulatory conditions that determine whether a small drug manufacturer or precision parts supplier can compete for the contracts and incentives that a reshoring agenda generates.

Access the Legis1 platform for comprehensive political news, data, and insights.